| Budget Amount *help |
¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2015: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2013: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
|---|
| Outline of Final Research Achievements |
Spinocerebellar ataxia type 6 (SCA6) is a neurodegenerative disease characterized by a slowly progressive loss of cerebellar Purkinje cell and motor impairments. In SCA6, a protein containing an expanded polyglutamine stretch gradually accumulates in the cerebellar Purkinje cells but the molecular mechanisms leading to neurodegeneration remains largely elusive. In this study, we have shown that neuroinflammation is involved in the pathogenesis of SCA6. More importantly, by modulating the activation of microglial cells in the cerebellum of a faithful mouse model of SCA6, we succeeded in ameliorating their neurodegenerative phenotypes in the early disease phase.
|
